Literature DB >> 20800559

Genomic instability and copy-number heterogeneity of chromosome 19q, including the kallikrein locus, in ovarian carcinomas.

Jane Bayani1, Paula Marrano, Cassandra Graham, Yingye Zheng, Lin Li, Dionyssios Katsaros, Heini Lassus, Ralf Butzow, Jeremy A Squire, Eleftherios P Diamandis.   

Abstract

Many tissue kallikrein (KLK) genes and proteins are candidate diagnostic, prognostic and predictive biomarkers for ovarian cancer (OCa). We previously demonstrated that the KLK locus (19q13.3/4) is subject to copy-number gains and structural rearrangements in a pilot study of cell lines and ovarian cancer primary tissues, shown to overexpress KLK gene family members. To determine the overall frequency of genomic instability and copy-number changes, a retrospective study was conducted using formalin-fixed paraffin embedded (FFPE) tissues. Eighty-one chemotherapy naïve serous OCas were examined using 3-colour fluorescence in situ hybridization (FISH) to identify structural and numerical changes on 19q, including the KLK locus; in addition to immunohistochemistry (IHC) for KLK6, which has been shown to be overexpressed in OCa. The KLK locus was subject to copy-number changes in ∼83% of cases: net gain in 51%, net loss in 30% and amplified in 2%; and found to be chromosomally unstable (p < 0.001). All cases showed a wide range of immuoreactivity for KLK6 by IHC. Although no strong correlation could be found with copy-number, the latter was contributing factor to the observed KLK6 protein overexpression. Moreover, univariate and multivariate analyses showed an association between the net loss of the KLK locus and longer disease-free survival. Interestingly, FISH analyses indicated that chromosome 19q was subjected to structural rearrangement in 62% of cases and was significantly correlated to tumor grade (p < 0.001). We conclude that numerical and structural aberrations of chromosome 19q, affect genes including the KLK gene members, may contribute to ovarian carcinoma progression and aggressiveness.
Copyright © 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20800559      PMCID: PMC3110681          DOI: 10.1016/j.molonc.2010.08.002

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  84 in total

1.  Chromosome abnormalities in ovarian adenocarcinoma: II. Prognostic impact of nonrandom chromosome abnormalities in 244 cases.

Authors:  R Taetle; M Aickin; L Panda; J Emerson; D Roe; F Thompson; J Davis; J Trent; D Alberts
Journal:  Genes Chromosomes Cancer       Date:  1999-05       Impact factor: 5.006

Review 2.  Cellular distribution of human tissue kallikreins: immunohistochemical localization.

Authors:  Constantina D Petraki; Panagiotis A Papanastasiou; Vassiliki N Karavana; Eleftherios P Diamandis
Journal:  Biol Chem       Date:  2006-06       Impact factor: 3.915

Review 3.  Chromosomal abnormalities in cancer.

Authors:  Stefan Fröhling; Hartmut Döhner
Journal:  N Engl J Med       Date:  2008-08-14       Impact factor: 91.245

4.  Prognostic significance of cell cycle proteins and genomic instability in borderline, early and advanced stage ovarian carcinomas.

Authors:  H. Blegen; N. Einhorn; K. Sjövall; A. Roschke; B. M. Ghadimi; L. M. McShane; B. Nilsson; K. Shah; T. Ried; G. Auer
Journal:  Int J Gynecol Cancer       Date:  2000-11       Impact factor: 3.437

5.  KLK5 and KLK7, two members of the human tissue kallikrein family, are differentially expressed in lung cancer.

Authors:  Chris Planque; Michèle de Monte; Serge Guyetant; Jérôme Rollin; Claire Desmazes; Valentine Panel; Etienne Lemarié; Yves Courty
Journal:  Biochem Biophys Res Commun       Date:  2005-04-22       Impact factor: 3.575

6.  Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer.

Authors:  Carla A Borgoño; Tadaaki Kishi; Andreas Scorilas; Nadia Harbeck; Julia Dorn; Barbara Schmalfeldt; Manfred Schmitt; Eleftherios P Diamandis
Journal:  Clin Cancer Res       Date:  2006-03-01       Impact factor: 12.531

7.  Kallikreins as microRNA targets: an in silico and experimental-based analysis.

Authors:  Tsz-fung F Chow; Megan Crow; Tammy Earle; Hala El-Said; Eleftherios P Diamandis; George M Yousef
Journal:  Biol Chem       Date:  2008-06       Impact factor: 3.915

8.  High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications.

Authors:  Kylie L Gorringe; Sharoni Jacobs; Ella R Thompson; Anita Sridhar; Wen Qiu; David Y H Choong; Ian G Campbell
Journal:  Clin Cancer Res       Date:  2007-08-15       Impact factor: 12.531

Review 9.  Diverse molecular pathways in ovarian cancer and their clinical significance.

Authors:  Carmela Ricciardelli; Martin K Oehler
Journal:  Maturitas       Date:  2009-02-03       Impact factor: 4.342

10.  Cause and consequences of genetic and epigenetic alterations in human cancer.

Authors:  B Sadikovic; K Al-Romaih; J A Squire; M Zielenska
Journal:  Curr Genomics       Date:  2008-09       Impact factor: 2.236

View more
  7 in total

1.  Genomic instability and copy-number heterogeneity of chromosome 19q, including the kallikrein locus, in ovarian carcinomas.

Authors:  Jane Bayani; Paula Marrano; Cassandra Graham; Yingye Zheng; Lin Li; Dionyssios Katsaros; Heini Lassus; Ralf Butzow; Jeremy A Squire; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2010-08-11       Impact factor: 6.603

2.  Clinical significance and novel mechanism of action of kallikrein 6 in glioblastoma.

Authors:  Kristen L Drucker; Alex R Paulsen; Caterina Giannini; Paul A Decker; Sachiko I Blaber; Michael Blaber; Joon H Uhm; Brian P O'Neill; Robert B Jenkins; Isobel A Scarisbrick
Journal:  Neuro Oncol       Date:  2013-01-10       Impact factor: 12.300

3.  Triplex DNA-binding proteins are associated with clinical outcomes revealed by proteomic measurements in patients with colorectal cancer.

Authors:  Laura D Nelson; Christian Bender; Heiko Mannsperger; Daniel Buergy; Patryk Kambakamba; Giridhar Mudduluru; Ulrike Korf; Dennis Hughes; Michael W Van Dyke; Heike Allgayer
Journal:  Mol Cancer       Date:  2012-06-08       Impact factor: 27.401

4.  Kallikrein-related peptidase 6 regulates epithelial-to-mesenchymal transition and serves as prognostic biomarker for head and neck squamous cell carcinoma patients.

Authors:  Carola H Schrader; Markus Kolb; Karim Zaoui; Christa Flechtenmacher; Niels Grabe; Klaus-Josef Weber; Thomas Hielscher; Peter K Plinkert; Jochen Hess
Journal:  Mol Cancer       Date:  2015-05-20       Impact factor: 27.401

5.  Clinical and genetic analysis of recurrent adult-type granulosa cell tumor of the ovary: Persistent preservation of heterozygous c.402C>G FOXL2 mutation.

Authors:  Satoshi Yanagida; Michael S Anglesio; Tayyebeh M Nazeran; Amy Lum; Momoko Inoue; Yasushi Iida; Hirokuni Takano; Takashi Nikaido; Aikou Okamoto; David G Huntsman
Journal:  PLoS One       Date:  2017-06-08       Impact factor: 3.240

6.  Prognostic significance of multiple kallikreins in high-grade astrocytoma.

Authors:  Kristen L Drucker; Caterina Gianinni; Paul A Decker; Eleftherios P Diamandis; Isobel A Scarisbrick
Journal:  BMC Cancer       Date:  2015-08-01       Impact factor: 4.430

Review 7.  Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy.

Authors:  Huimin Bai; Dongyan Cao; Jiaxin Yang; Menghui Li; Zhenyu Zhang; Keng Shen
Journal:  J Cell Mol Med       Date:  2016-01-22       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.